AMBS is trying to position itself so that at the JP Morgan Conference in January, it will be the Belle of the Ball:

LymPro Launch,
MANF/RP Orphan,
MANF/Wolfram's/Eye Data,
Eltoprazine 2b Clinical Trial,
ESS Orphan
Phenoguard's "Plethora" of other discoveries.

I THINK INSTITUTIONS WILL SEE A BUYING OPPORTUNITY once AMBS up lists in late January or early February. Dr. Rubenfeld may replace Gerald as our go to guy SPOKESMAN because of his credibility.